Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02666599
Overview
The objective of the study is to evaluate the sensibility of the probe Forimtech to detect β+ emission in vivo in humans and its usefulness during elective surgical procedure Hypothesis:The probe Forimtech is able to allow per-surgery detection of tumoral lesions sensible to 18F-FDG and to help in the realization of guided biopsies, minimally invasive surgery or complement of resection of tumors. The β+ emission detected by the probe Forimtech is correlated to the emission γ detected by the 18F-FDG.PET/CT
Sponsor
University of Lausanne Hospitals
Phase
N/A
Contacts
John O Prior, PhD MD (Principal Investigator)
john.prior@chuv.ch
+41 21 314 43 48
Christine Geldhof
christine.geldhof@chuv.ch
+41 21 314 43 46
ClinicalTrials.gov
NCT02666599Drug / Compound
Help us improve your experience